FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:1678-1683 June 22, 1995 Number 25 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Intensive chemotherapy for acute myelogenous leukemia (AML) continues to yield low rates of complete remission and survival among patients over the age of 65 years. Infection-related mortality is particularly high among these patients during the period of neutropenia that follows chemotherapy. We determined the effect of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) on mortality at eight weeks (the main end point) and the rate of complete remission among patients with AML who were 65 years old or older.

Methods After induction chemotherapy with daunorubicin (45 mg per square meter of body-surface area per day for 4 days) and cytarabine (200 mg per square meter per day for 7 days), 173 patients with newly diagnosed AML were randomly assigned on day 8 to receive either lenograstim (5 µg per kilogram of body weight per day) or placebo, starting on day 9, until there was neutrophil recovery or a treatment failure, or for a maximum of 28 days. Salvage chemotherapy was also followed by lenograstim or placebo. Patients with a complete remission received two consolidation courses of chemotherapy without lenograstim or placebo.

Results The mortality rate at eight weeks was similar in the lenograstim and placebo groups (23 and 27 percent, respectively; P = 0.60), as was the incidence of severe infections. The median duration of neutropenia (absolute neutrophil count, <1000 per cubic millimeter) was shorter in the lenograstim group (21 days, as compared with 27 days in the placebo group; P<0.001). Eight percent of the patients in both groups had regrowth of AML cells. The rate of complete remission was significantly higher in the lenograstim group (70 percent, as compared with 47 percent in the placebo group; P = 0.002). Overall survival, however, was similar in the two groups (P = 0.76).

Conclusions The administration of lenograstim after chemotherapy for AML did not decrease the mortality rate at eight weeks among patients over the age of 65 years. The patients who received lenograstim had a significantly higher rate of complete remission than those who received placebo. Nevertheless, the overall survival in the two groups did not differ significantly.

Source Information

From Hôpital Saint-Louis (H.D., C.C., L.D.) and Hôpital du Val-de-Grace (G.A.), Paris; Hôpital Claude Huriez, Lille (P.F.); Hôpital Haut Lévêque, Pessac (J.R.); Hôpital Dupuytren, Limoges (D.B.); Institut Paoli Calmettes, Marseilles (R.B.); Centre Henri Becquerel, Rouen (H.T.); and Chugai-Rhône-Poulenc, Antony (A.Y.) — all in France; Università La Sapienza, Rome (F.M.); and Cliniques Universitaires Saint-Luc, Brussels, Belgium (A.F.).

Address reprint requests to Dr. Dombret at Hôpital Saint-Louis, Service Clinique des Maladies du Sang, 1, Avenue Claude Vellefaux, 75010, Paris, France.

Full Text of this Article

Related Letters:

Recombinant Granulocyte Colony-Stimulating Factor in Acute Myelogenous Leukemia
Munck J.-N., Deacaudin D., Koscielny S., Dombret H., Chastang C., The AML Cooperative Study Group
Extract | Full Text  
N Engl J Med 1995; 333:1155-1156, Oct 26, 1995. Correspondence

This article has been cited by other articles:

• Sung, L., Nathan, P. C., Alibhai, S. M.H., Tomlinson, G. A., Beyene, J. (2007). Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection. ANN INTERN MED 147: 400-411 [Abstract] [Full Text]  
• Gardin, C., Turlure, P., Fagot, T., Thomas, X., Terre, C., Contentin, N., Raffoux, E., de Botton, S., Pautas, C., Reman, O., Bourhis, J.-H., Fenaux, P., Castaigne, S., Michallet, M., Preudhomme, C., de Revel, T., Bordessoule, D., Dombret, H., for the Acute Leukemia French Association (ALFA), (2007). Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy:results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 109: 5129-5135 [Abstract] [Full Text]  
• Hershman, D., Neugut, A. I., Jacobson, J. S., Wang, J., Tsai, W.-Y., McBride, R., Bennett, C. L., Grann, V. R. (2007). Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy. JNCI J Natl Cancer Inst 99: 196-205 [Abstract] [Full Text]  
• Lehrnbecher, T., Zimmermann, M., Reinhardt, D., Dworzak, M., Stary, J., Creutzig, U. (2007). Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood 109: 936-943 [Abstract] [Full Text]  
• Erba, H. P. (2007). Prognostic Factors in Elderly Patients with AML and the Implications for Treatment. ASH Education Book 2007: 420-428 [Abstract] [Full Text]  
• Milligan, D. W., Wheatley, K., Littlewood, T., Craig, J. I. O., Burnett, A. K., for the NCRI Haematological Oncology Clinical Stud, (2006). Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood 107: 4614-4622 [Abstract] [Full Text]  
• Stock, W. (2006). Controversies in Treatment of AML: Case-based Discussion. ASH Education Book 2006: 185-191 [Abstract] [Full Text]  
• Chen, C.-C., Yang, C.-F., Yang, M.-H., Lee, K.-D., Kwang, W.-K., You, J.-Y., Yu, Y.-B., Ho, C.-H., Tzeng, C.-H., Chau, W.-K., Hsu, H.-C., Gau, J.-P. (2005). Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia. Ann Oncol 16: 1366-1373 [Abstract] [Full Text]  
• Amadori, S., Suciu, S., Jehn, U., Stasi, R., Thomas, X., Marie, J.-P., Muus, P., Lefrere, F., Berneman, Z., Fillet, G., Denzlinger, C., Willemze, R., Leoni, P., Leone, G., Casini, M., Ricciuti, F., Vignetti, M., Beeldens, F., Mandelli, F., De Witte, T., for the EORTC/GIMEMA Leukemia Groups, (2005). Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 106: 27-34 [Abstract] [Full Text]  
• Lancet, J. E., Karp, J. E. (2003). Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 102: 3880-3889 [Abstract] [Full Text]  
• Mengis, C., Aebi, S., Tobler, A., Dahler, W., Fey, M. F. (2003). Assessment of Differences in Patient Populations Selected for or Excluded From Participation in Clinical Phase III Acute Myelogenous Leukemia Trials. JCO 21: 3933-3939 [Abstract] [Full Text]  
• Relling, M. V., Boyett, J. M., Blanco, J. G., Raimondi, S., Behm, F. G., Sandlund, J. T., Rivera, G. K., Kun, L. E., Evans, W. E., Pui, C.-H. (2003). Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 101: 3862-3867 [Abstract] [Full Text]  
• Goldstone, A. H., Burnett, A. K., Wheatley, K., Smith, A. G., Hutchinson, R. M., Clark, R. E. (2001). Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 98: 1302-1311 [Abstract] [Full Text]  
• Stone, R. M., Berg, D. T., George, S. L., Dodge, R. K., Paciucci, P. A., Schulman, P. P., Lee, E. J., Moore, J. O., Powell, B. L., Baer, M. R., Bloomfield, C. D., Schiffer, C. A. (2001). Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98: 548-553 [Abstract] [Full Text]  
• Boushey, R. P., Yusta, B., Drucker, D. J. (2001). Glucagon-like Peptide (GLP)-2 Reduces Chemotherapy-associated Mortality and Enhances Cell Survival in Cells Expressing a Transfected GLP-2 Receptor. Cancer Res. 61: 687-693 [Abstract] [Full Text]  
• Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., Wade, J. L. III, Winn, R. J., Wozniak, A. J., Somerfield, M. R., for the American Society of Clinical Oncology Gro, (2000). 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. JCO 18: 3558-3585 [Full Text]  
• Bruserud, O., Tjønnfjord, G., Gjertsen, B. T., Foss, B., Ernst, P. (2000). New Strategies in the Treatment of Acute Myelogenous Leukemia: Mobilization and Transplantation of Autologous Peripheral Blood Stem Cells in Adult Patients. Stem Cells 18: 343-351 [Abstract] [Full Text]  
• Archimbaud, E., Ottmann, O. G., Yin, J. A. L., Lechner, K., Dombret, H., Sanz, M. A., Heil, G., Fenaux, P., Brugger, W., Barge, A., O'Brien-Ewen, C., Matcham, J., Hoelzer, D. (1999). A Randomized, Double-Blind, Placebo-Controlled Study With Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF) as an Adjunct to Chemotherapy for Adults With De Novo Acute Myeloid Leukemia. Blood 94: 3694-3701 [Abstract] [Full Text]  
• Hiddemann, W., Kern, W., Schoch, C., Fonatsch, C., Heinecke, A., Wormann, B., Buchner, T. (1999). Management of Acute Myeloid Leukemia in Elderly Patients. JCO 17: 3569-3576 [Abstract] [Full Text]  
• Lowenberg, B., Downing, J. R., Burnett, A. (1999). Acute Myeloid Leukemia. NEJM 341: 1051-1062 [Full Text]  
• Estey, E. H., Thall, P. F., Pierce, S., Cortes, J., Beran, M., Kantarjian, H., Keating, M. J., Andreeff, M., Freireich, E. (1999). Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin ± All-Trans Retinoic Acid ± Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood 93: 2478-2484 [Abstract] [Full Text]  
• Godwin, J. E., Kopecky, K. J., Head, D. R., Willman, C. L., Leith, C. P., Hynes, H. E., Balcerzak, S. P., Appelbaum, F. R. (1998). A Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031). Blood 91: 3607-3615 [Abstract] [Full Text]  
• Witz, F., Sadoun, A., Perrin, M.-C., Berthou, C., Briere, J., Cahn, J.-Y., Lioure, B., Witz, B., Francois, S., Desablens, B., Pignon, B., Le Prise, P.-Y., Audhuy, B., Caillot, D., Casassus, P., Delain, M., Christian, B., Tellier, Z., Polin, V., Hurteloup, P., Harousseau, J.-L. (1998). A Placebo-Controlled Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Administered During and After Induction Treatment for De Novo Acute Myelogenous Leukemia in Elderly Patients. Blood 91: 2722-2730 [Abstract] [Full Text]  
• Heil, G., Hoelzer, D., Sanz, M. A., Lechner, K., Liu Yin, J. A., Papa, G., Noens, L., Szer, J., Ganser, A., O'Brien, C., Matcham, J., Barge, A. (1997). A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia. Blood 90: 4710-4718 [Abstract] [Full Text]  
• Lowenberg, B., Suciu, S., Archimbaud, E., Ossenkoppele, G., Verhoef, G.E.G., Vellenga, E., Wijermans, P., Berneman, Z., Dekker, A.W., Stryckmans, P., Schouten, H., Jehn, U., Muus, P., Sonneveld, P., Dardenne, M., Zittoun, R. (1997). Use of Recombinant Granulocyte-Macrophage Colony-Stimulating Factor During and After Remission Induction Chemotherapy in Patients Aged 61 Years and Older With Acute Myeloid Leukemia (AML): Final Report of AML-11, a Phase III Randomized Study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 90: 2952-2961 [Abstract] [Full Text]  
• Geissler, K., Koller, E., Hubmann, E., Niederwieser, D., Hinterberger, W., Geissler, D., Kyrle, P., Knobl, P., Pabinger, I., Thalhammer, R., Schwarzinger, I., Mannhalter, C., Jaeger, U., Heinz, R., Linkesch, W., Lechner, K. (1997). Granulocyte Colony-Stimulating Factor as an Adjunct to Induction Chemotherapy for Adult Acute Lymphoblastic Leukemia --- A Randomized Phase-III Study. Blood 90: 590-596 [Abstract] [Full Text]  
• Pui, C.-H., Boyett, J. M., Hughes, W. T., Rivera, G. K., Hancock, M. L., Sandlund, J. T., Synold, T., Relling, M. V., Ribeiro, R. C., Crist, W. M., Evans, W. E. (1997). Human Granulocyte Colony-Stimulating Factor after Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia. NEJM 336: 1781-1787 [Abstract] [Full Text]  
• Leith, C. P., Kopecky, K. J., Godwin, J., McConnell, T., Slovak, M. L., Chen, I-M., Head, D. R., Appelbaum, F. R., Willman, C. L. (1997). Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study. Blood 89: 3323-3329 [Abstract] [Full Text]  
• Moore, J. O., Dodge, R. K., Amrein, P. C., Kolitz, J., Lee, E. J., Powell, B., Godfrey, S., Robert, F., Schiffer, C. A. (1997). Granulocyte Colony-Stimulating Factor (Filgrastim) Accelerates Granulocyte Recovery After Intensive Postremission Chemotherapy for Acute Myeloid Leukemia With Aziridinyl Benzoquinone and Mitoxantrone: Cancer and Leukemia Group B Study 9022 . Blood 89: 780-788 [Abstract] [Full Text]  
• Munck, J.-N., Deacaudin, D., Koscielny, S., Dombret, H., Chastang, C., The AML Cooperative Study Group, (1995). Recombinant Granulocyte Colony-Stimulating Factor in Acute Myelogenous Leukemia. NEJM 333: 1155-1156 [Full Text]  
• Hamblin, T. J. (1995). Disappointments in Treating Acute Leukemia in the Elderly. NEJM 332: 1712-1714 [Full Text]